Pfizer (PFE) Chief Executive Albert Bourla said that no agreements have been reached in recent drug pricing-related talks between the US government and pharmaceutical companies, according to a FactSet transcript of a Goldman Sachs healthcare conference Monday.
The discussions with the Trump administration were "cordial" and did not include specific proposals, Bourla said at the conference, according to the transcript.
US President Donald Trump issued an executive order on May 12 aimed at cutting US drug prices by linking them to international rates.
Bourla also said Pfizer may consider excluding some products from government reimbursement programs in European countries where prices remain low, though he said the company does not plan to pull those products from the market entirely.
"We prefer to find a solution that can motivate Europeans to do a little bit more, can motivate the pharmaceutical companies to reduce their prices, but also in a way that it's sustainable for the industry," Bourla said, the transcript showed.
Price: 23.72, Change: +0.38, Percent Change: +1.65
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。